Trial Profile
A trial to evaluate the effectiveness of natalizumab in patients with highly active, relapsing-remitting multiple sclerosis (HA-RRMS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 04 May 2016 New trial record